EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation

Launched by AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITA · Feb 22, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well Edoxaban, a medication used to prevent blood clots, works in patients who have a feeding tube (called a PEG) and a heart condition known as atrial fibrillation. The study aims to compare Edoxaban with other blood-thinning medications to see which one is more effective and how patients feel about their treatment over time. Participants will take Edoxaban once a day, and their experiences will be evaluated through a questionnaire at 6 and 12 months to understand how well the treatment is working for them.

To join the study, participants need to be between 65 and 74 years old and have a PEG tube in place for long-term feeding. They also need to have a medical reason for being on blood-thinning medications. However, those under 18, with a very short life expectancy, or who cannot provide informed consent will not be eligible. This trial is currently recruiting participants, and it provides an opportunity for patients to contribute to important research that could improve treatment options for others in similar situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • PEG (recent implantation or already present)
• • Indication for long-term oral anticoagulation
• Exclusion Criteria:
• • Under 18 years of age
• • Life expectancy \<30 days
• • Lack of informed consent
• • Contraindication to DOACs